Radiopharm Theranostics Limited RADX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -79.31%
- 1 year
- -79.11%
- Open
- 1.09
- Prev close
- 1.12
- Mkt cap
- 16.96M
- Vol
- 8.37K
- Avg vol
- 55.33K
- EPS
- -3.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.08
- High
- 1.16
- Forward P/E
- 0.00
- Beta
- 0.85
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 7.67
- 200-d avg
- 7.67
- 1y target
- 0.00
6M chart
Signals (20)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 2, 2026 | 1 month ago |
| RSI: Oversold | Sep 28, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 15, 2026 | 1 month ago |
| RSI: Oversold | Sep 1, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 24, 2026 | 2 months ago |
| RSI: Oversold | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 24, 2026 | 3 months ago |
| RSI: Oversold | Jul 24, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 2, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | May 14, 2026 | 5 months ago |
| MACD: Buy Signal | May 14, 2026 | 5 months ago |
| MACD: Sell Signal | May 6, 2026 | 5 months ago |
| MACD: Buy Signal | May 5, 2026 | 6 months ago |
Key statistics
- Market cap
- 0
- Enterprise value
- 9.52B
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 69.02
- EPS (TTM)
- -0.08
- Beta
- 0.85
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.96M
- Revenue growth
- 0.00%
- Free cash flow
- -12.04M
- Total cash
- 18.58M
- Total debt
- 0
- Return on equity
- -131.49%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 7.67
- 200-day average
- 7.67
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Radiopharm Theranostics Limited
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. The company was incorporated in 2021 and is based in Carlton, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- radiopharmtheranostics.com
News
Your note
Sign in to keep a note on RADX — it syncs with the Stock Master app.